I assumed the 1 mil shares you're referring to is in respect to cell I3; this can be any amount whether it be 100K or 1 Mil - it does not affect the EPS (as the formula is independent of the number of units held by an investor) except the dollar value of an expected dividend.
EPS or Earnings Per Share is in this case; NPAT divided by the Total Shares on Issued; i.e. 0.49 for 2025 FY - if we assumed a 30% of this to be paid out as dividend = 0.147 or 0.15/share; the net dividend dollar value you would receive is 0.15/share x X. number of units; hope this make sense.
1. Yes, if you refer to LTR's original graph illustrating the pre-production cost of $545 m; it include $46 m in Contingency & Escalation. As there was no detail provided on the split between Contingency & Escalation, FEED Scope Optimisations, Capitalised Pre-Production Expenses and Construction Capex - thus I've up Contingency ($40m) & Escalation to $80 m for now until LTR provided a further update.
2. Yes I did; as per FY22 Financial; the carry forward losses in the balance sheet was $112 m; I added 30% to this to account the additional overhead cost for FY23 - note that there is a difference between accounting loss and tax loss - I could not locate the latter and thus rely on the provided figure for now.
3. There's no backing at the moment to provide for this amount as it is just a provisional amount that can be used towards debt repayment, working capital, capex sustaining, etc. It can be higher or lower depending on the BOD's decision at that time; given there are surplus fund even after making a provision - they can up this provision say to pay off debt earlier or even make strategic acquisition from this provision.
LTR Price at posting:
$1.38 Sentiment: Buy Disclosure: Held
(20min delay)